Sino Biological Inc. offers latest and comprehensive custom services for over 10 years. To accelerate life science research and development, Sino Biological assists the customers worldwide with all passions and great efforts. Today, Sino is proud to be strong backup for clients, with our professional scientists, experienced researchers, advanced instrument, compliant facility, proprietary technology platform, and optimized processes. | ![]() |
Recombinant Protein Production Service
• Baculovirus-insect expression |
![]() |
Fig 1. SDS-PAGE >97% |
• E.coli expression |
![]() |
Fig 2. Cell bioactivity: EC50=17pg/mL |
• HEK293 / CHO transient expression |
![]() |
Fig 3. SEC-HPLC >98.2% |
Antibody Production & Development Service
• Recombinant antibody production |
![]() |
Fig 1. SDS-PAGE electrophoresis |
• Standard Rabbit Pab development |
![]() |
Fig 2. Immunofluorescence staining of mouse target A in NIH-3T3 cells. Positive staining was localized to Mitochondrion. |
• Standard Mouse Mab development |
![]() |
Fig 3. Immunochemical staining of human target D in human breast carcinoma with mouse Mab. |
• Rabbit Mab development |
![]() |
Fig 4. Immunochemical staining of human target E in human gastric cancer with rabbit Mab. The image showing membrane staining of epithelium cell. |
Protein Production Service | • High-efficiency expression vectors |
• High cell density culturing | |
• Proprietary medium formulation | |
• >6000 proteins expression and purification experience | |
• Inclusion body refolding & soluble expression | |
• Protein biopharmaceutical technology |
Antibody Production & development Service | • Hybridoma & phage display library technology |
• Multiple validation platforms: ELISA, IHC, IF, WB, FACS, IP, ICC and functional assays | |
• Varied antibody screening and purification technology | |
• The five protein expression platforms for antigen and recombinant antibody preparation |
Biopharmaceutical Service | • Successfully screened dozens of candidate antibodies with high activity and druggability against several key targets |
• Established cell activity evaluation models for many antibodies against key drug targets (PD-1, PD-L1, and EGFR, etc) | |
• A full set of preclinical research experience for multiple drug targets |